Citation may avoid plagiarism, but there can be other problems
The September 1, 2006 issue of Science has a variation on this: the use of review articles to present data that isn't in the primary literature. Thus, even though one has a cite for a proposition (the review article), there is no presentation of actual data for the proposition.
Propagation of Errors in Review Articles, Thomas J. Katz, Dept of Chemistry, Columbia University [IPBiz: recall the role Columbia University in the Rogerio Lobo incident about prayer. recall also the problem in the Dept of Chemistry with the Sezen Sames incident.]
...journals are sometimes reluctant to publicize mistakes (3). The fact is that science does not always self-correct; it has to be corrected.
Ref (3) is J. Couzin, Science 312, 38 (2006)
Katz is complaining about C.P. Casey, J. Chem. Ed., 83, 192 (2006) and citing himself in Angew. Chem. Int. Ed. 44, 3010 (2005).
At SSI-11, I gave an example of an article in the journal Energy & Fuels (a publication of the American Chemical Society) wherein the authors had cited to a non-existent journal. Even after recognizing this truth, the editor refused to correct the mistake.
The third paper on patent grant rate by Quillen and Webster in Fed Cir Bar Journal, purportedly confirming numbers in the previous two papers, offers a different twist.
For a discussion of flagrant plagiarism (ie, reproduce an article word-for-word but remove the name of the true author and substitute someone else), look
Two other papers of relevance in the Sept 1 issue of Science:
J.A. Gladysz, Fluorous to the core, 313 Science 1249
Thus, in constrast to the inaccessible interiors of large fullerenes
[IPBiz: recall all those studies on "endohedral" fullerenes, including studies on drugs included in fullerenes.]
this initial study is certain to be followed by many exciting discoveries
[IPBiz: recall the language of Moses Gomberg on hexaphenyl ethane.]
Letter, Why Academic Drug Discovery Makes Sense, 313 Science 1235
rising costs of industrial drug discovery are largely associated with failed paradigms
there is no willingness to reinvigorate cheaper off-patent versions of approved medications for common diseases
by Alan P. Kozikowski
[IPBiz post 1961]